Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma.
暂无分享,去创建一个
R Bucholz | M. Berger | M. Prados | A. Asher | W. Hall | R. Puri | F. Floeth | R. Bucholz | N. Rainov | M. Westphal | J. Bruce | R. Warnick | F. Weber | R K Puri | S Chang | M Prados | R W Rand | M Westphal | F W Weber | F Floeth | A Asher | M Berger | J Bruce | W Hall | N G Rainov | R E Warnick | F Rommell | H Pan | V N Hingorani | R. Rand | H. Pan | V. Hingorani | S. Chang | F. Rommell
[1] M. Vogelbaum,et al. IL-13R(alpha)2, a decoy receptor for IL-13 acts as an inhibitor of IL-4-dependent signal transduction in glioblastoma cells. , 2002, Cancer research.
[2] S. Piantadosi,et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas , 1995, The Lancet.
[3] R. Puri,et al. In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures. , 2001, Cancer research.
[4] C. Osborne,et al. Targeting the EGF receptor in breast cancer treatment , 2004, Breast Cancer Research and Treatment.
[5] I. Pastan,et al. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[6] I. Pastan,et al. An improved circularly permuted interleukin 4-toxin is highly cytotoxic to human renal cell carcinoma cells. Introduction of gamma c chain in RCC cells does not improve sensitivity. , 1996, Cellular immunology.
[7] R. Puri,et al. Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas. , 2000, Cancer research.
[8] G. Barnett,et al. In vivo expression of the interleukin 4 receptor alpha by astrocytes in epilepsy cerebral cortex. , 2000, Cytokine.
[9] Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990-1994. , 1999, Neuro-oncology.
[10] I. Pastan,et al. Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma. , 1995, Cancer research.
[11] W. Jin,et al. Glioblastoma cell-specific expression of fibroblast growth factor receptor-1beta requires an intronic repressor of RNA splicing. , 1999, Cancer research.
[12] D. Frappaz,et al. Is reoperation for recurrence of glioblastoma justified? , 2000, Oncology reports.
[13] I. Pastan,et al. Complete regression of established human glioblastoma tumor xenograft by interleukin-4 toxin therapy. , 1998, Cancer research.
[14] P F Morrison,et al. Convection-enhanced delivery of macromolecules in the brain. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[15] R. Puri,et al. Interleukin‐13 receptor as a unique target for anti‐glioblastoma therapy , 2001, International journal of cancer.
[16] R. McLendon,et al. Tumor antigens in astrocytic gliomas , 1995, Glia.
[17] I. Pastan,et al. Human neurological cancer cells express interleukin‐4 (IL‐4) receptors which are targets for the toxic effects of IL4‐pseudomonas exotoxin chimeric protein , 1994, International journal of cancer.
[18] L. Polito,et al. Immunoconjugates made of an anti-EGF receptor monoclonal antibody and type 1 ribosome-inactivating proteins from Saponaria ocymoides or Vaccaria pyramidata. , 1997, British Journal of Cancer.
[19] E. Oldfield,et al. Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice. , 1994, Journal of neurosurgery.
[20] I. Pastan,et al. A circularly permuted recombinant interleukin 4 toxin with increased activity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[21] E. Oldfield,et al. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors , 1997, Nature Medicine.
[22] I. Pastan,et al. Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma. , 1996, Cancer research.
[23] P F Morrison,et al. Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. , 1995, Journal of neurosurgery.